Table 4 Interventions and outcomes of included trials
Study ID | Intervention | Duration/ follow up | Outcome measures | Adverse event | |
|---|---|---|---|---|---|
Trial group | Control group | ||||
Hu (2001) [32] | MSJZT | Pantoprazole | 4 weeks/ NM | 1) Response rate 2) Gastric emptying | NM |
Cao (2008) [33] | MSJZT | Pantoprazole | 4 weeks/ NM | Response rate | NM |
Li (2008) [34] | SJZT | Pantoprazole | 4 weeks/ 2 months | Response rate | Control group: 8 cases with abdominal discomfort, bloating, diarrhea |
Deng and Su (2010)a [31] | MSJZT (High dose) | Pantoprazole | 4 weeks/ NM | Response rate | NM |
Deng and Su (2010)b [31] | MSJZT (low dose) | Pantoprazole | 4 weeks/ NM | Response rate | NM |
Mu (2012) [35] | SJZT + Domperidone + Omeprazole | Domperidone + Omeprazole | 4 weeks/ NM | Response rate | NO |
Zhang (2013) [36] | SJZT + Mosapride Citrate | Mosapride Citrate | 4 weeks/ 6 months | 1) Response rate 2) Relapse rate | NM |
Lv (2014) [37] | MSJZT | Placebo | 4 weeks | 1) Quality of life 2) Response rate 3) Gastric emptying | NO |
Zhang (2014) [38] | MSJZT | Placebo | 4 weeks/ NM | 1) Quality of life 2) Response rate | NO |
Lan and Yuan (2016) [39] | MSJZT | Pantoprazole | 4 weeks/ NM | Response rate | NM |
Liu et al. (2016) [40] | MSJZT + Domperidone | Domperidone | 8 weeks/ NM | Response rate | NO |
Li (2016) [41] | MSJZT | Domperidone | 60 days/ 6 months | 1) Response rate 2) Relapse rate | NM |